Fenwick & West LLP represented Sutro Biopharma, Inc., the developers of a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies, in a collaboration with Celgene Corporation to create and develop novel antibody drug conjugates (ADCs) and bispecific antibodies for two undisclosed targets and to manufacture a proprietary Celgene antibody. Sutro will be responsible for product design and production of preclinical materials using the company’s proprietary, cell-free protein synthesis technology. Sutro will receive a substantial upfront payment, an equity investment in the company and payments for the completion of research, development and regulatory milestones, bringing the potential deal value to over $500 million for Sutro.

The Fenwick transaction team was led by corporate partner Effie Toshav and included corporate partner Matthew Rossiter and technology transactions associate Stefano Quintini.


Don’t have an account yet?